title: Higher insulin detemir doses are required for the similar glycemic control: comparison of insulin detemir and glargine in children with type 1 diabetes mellitus.
abstract: OBJECTIVE
  We aimed to compare hemoglobin A1c (HbA1c), total and basal insulin doses, basal insulin injection frequencies, and body mass index (BMI) in children with type 1 diabetes mellitus (T1DM) who are receiving detemir and glargine as basal insulin in a basal-bolus therapy.
  
  
  METHODS
  This retrospective study included 117 (53 females) children and adolescents with T1DM older than 4 yr of age, minimum diabetes duration of 2 yr, and receiving basal-bolus insulin regimen (at least 4 injections/d, insulin aspart or lispro as bolus insulin). Comparisons were made for those receiving insulin detemir (n = 32) or glargine (n = 85) as the basal insulin.
  
  
  RESULTS
  Age, pubertal status, BMI standard deviation scores, and diabetes duration were similar in detemir and glargine groups. Glycemic control was similar in both groups (HbA1c levels 8.9 ± 2.1% vs. 8.5 ± 1.7% for detemir and glargine, respectively; p = 0.497). Both mean basal insulin (0.52 vs. 0.41 U/kg/d, p < 0.001) and mean total daily insulin (1.11 vs. 0.93 U/kg/d, p < 0.001) doses were higher in the detemir group. Furthermore, higher ratio of twice-daily basal insulin injection was detected in the detemir group (62.5 vs. 32.9% p = 0.004). Subgroup analysis according to pubertal status, or the number of daily basal injections showed similar results.
  
  
  CONCLUSIONS
  Insulin detemir provides similar glycemic control with glargine, but, approximately 27% higher mean basal and 19% higher mean total insulin doses with two-fold more twice-daily basal insulin injection requirement.
authors.affiliation: Department of Paediatric Endocrinology and Diabetes, Marmara University, School of Medicine, Istanbul, Turkey.
authors.forename: Saygın
authors.initials: S
authors.lastname: Abalı
authors.affiliation: Department of Paediatric Endocrinology and Diabetes, Marmara University, School of Medicine, Istanbul, Turkey.
authors.forename: Serap
authors.initials: S
authors.lastname: Turan
authors.affiliation: Department of Paediatric Endocrinology and Diabetes, Marmara University, School of Medicine, Istanbul, Turkey.
authors.forename: Zeynep
authors.initials: Z
authors.lastname: Atay
authors.affiliation: Department of Paediatric Endocrinology and Diabetes, Marmara University, School of Medicine, Istanbul, Turkey.
authors.forename: Tülay
authors.initials: T
authors.lastname: Güran
authors.affiliation: Department of Paediatric Endocrinology and Diabetes, Marmara University, School of Medicine, Istanbul, Turkey.
authors.forename: Belma
authors.initials: B
authors.lastname: Haliloğlu
authors.affiliation: Department of Paediatric Endocrinology and Diabetes, Marmara University, School of Medicine, Istanbul, Turkey.
authors.forename: Abdullah
authors.initials: A
authors.lastname: Bereket
mesh_terms: D000293:Adolescent; D001786:Blood Glucose / Q000187:drug effects* / Q000378:metabolism; D002648:Child; D003922:Diabetes Mellitus, Type 1 / Q000097:blood / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D006442:Glycated Hemoglobin / Q000032:analysis; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage*; D007267:Injections; D000069057:Insulin Detemir / Q000008:administration & dosage*; D000069036:Insulin Glargine / Q000008:administration & dosage*; D008297:Male; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D001786:Blood Glucose; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D000069057:Insulin Detemir; D000069036:Insulin Glargine
keywords: HbA1c; T1D; children; detemir; glargine